Publication | Open Access

LBA93 EXTENTORCH: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC)

OncologyPhase Iii TrialToripalimab Versus PlaceboBronchial NeoplasmImmune Checkpoint InhibitorLba93 ExtentorchCancer TreatmentMedicineRadiation OncologyLung Cancer